Holmberg Erica, Ahn Henrik, Peterzén Bengt
a Department of Cardiothoracic and Vascular Surgery , University Hospital and Department of Medical and Health Sciences, Linköping University , Linköping , Sweden.
Scand Cardiovasc J. 2017 Dec;51(6):293-298. doi: 10.1080/14017431.2017.1388536. Epub 2017 Oct 13.
Over recent decades implantable left ventricular assist devices (LVAD) have increased the possibility of improved survival in patients with advanced heart failure who also benefit from a better quality of life. The aim of this retrospective survey was to review the clinical results of LVAD implantation at a low-volume non-transplant centre (Linköping, Sweden) between 1993 and 2016. Our aim was also to assess the mortality and morbidity rates associated with implantation of three LVAD versions at our centre, and to compare our results with those from transplant centres.
A retrospective cohort study was performed examining the medical records of patients who had a HeartMate (HMI, HMII, HMIII) LVAD implanted as a bridge to heart transplantation (BTT) or as destination therapy (DT) at the University Hospital, Linköping.
Our main finding was a survival to heart transplantation rate of 82% among our BTT LVAD patients. The most common adverse event among our patients was infection. A higher frequency of temporary dialysis was seen in the HMII group compared to the HMI group, and the frequency of right ventricular failure was higher in our HMII material.
Our data suggests that patients requiring long-term LVAD support can safely have their device implanted and cared for at a non-transplant centre.
在最近几十年中，植入式左心室辅助装置（LVAD）提高了晚期心力衰竭患者改善生存的可能性，这些患者的生活质量也得到了改善。这项回顾性调查的目的是回顾1993年至2016年期间在瑞典林雪平的一个低容量非移植中心进行LVAD植入的临床结果。我们的目的还包括评估在我们中心植入三种LVAD型号相关的死亡率和发病率，并将我们的结果与移植中心的结果进行比较。
进行了一项回顾性队列研究，检查在林雪平大学医院接受HeartMate（HMI、HMII、HMIII）LVAD植入作为心脏移植桥接（BTT）或终末治疗（DT）的患者的病历。
我们的主要发现是，在我们接受BTT LVAD治疗的患者中，心脏移植生存率为82%。我们患者中最常见的不良事件是感染。与HMI组相比，HMII组临时透析的频率更高，并且在我们的HMII材料中右心室衰竭的频率更高。
我们的数据表明，需要长期LVAD支持的患者可以在非移植中心安全地植入和护理该装置。
